Drug Development | Novartis

Media Release
Jul 29, 2024
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Story
Apr 08, 2024
Drug delivery, service delivery, and the future of cancer care
Media Release
Dec 06, 2023
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Story
Dec 12, 2023
Innovation fueled by compassion
Story
Dec 08, 2023
Shoulder to shoulder
Media Release
Nov 20, 2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Story
Sep 08, 2023
Treatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
Story
Nov 01, 2022
A scientist from the start – Q&A with NIBR President Fiona Marshall
Story
Jun 23, 2022
Renewing our commitment to neglected tropical disease and malaria elimination
Featured News
May 23, 2022
Novartis at ASCO and EHA 2022
Media Release
Jan 10, 2022
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Media Release
Dec 20, 2021
Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)